Compare RSI & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSI | TSHA |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | RSI | TSHA |
|---|---|---|
| Price | $18.53 | $5.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $21.71 | $10.56 |
| AVG Volume (30 Days) | 1.4M | ★ 3.4M |
| Earning Date | 02-25-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $1,063,702,000.00 | $6,310,000.00 |
| Revenue This Year | $21.74 | N/A |
| Revenue Next Year | $16.27 | N/A |
| P/E Ratio | $60.31 | ★ N/A |
| Revenue Growth | ★ 23.15 | N/A |
| 52 Week Low | $9.54 | $1.05 |
| 52 Week High | $22.65 | $6.02 |
| Indicator | RSI | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 45.63 | 50.81 |
| Support Level | $18.71 | $4.80 |
| Resistance Level | $19.97 | $6.02 |
| Average True Range (ATR) | 0.74 | 0.33 |
| MACD | -0.10 | -0.10 |
| Stochastic Oscillator | 19.66 | 43.03 |
Rush Street Interactive Inc is an online gaming and entertainment company that focuses on online casinos and online sports betting in the U.S. and Latin American markets. It provides customers with an array of gaming offerings such as real-money online casinos, online sports betting, and retail sports betting, as well as social gaming, which involves free-to-play games that use virtual credits that can be earned or purchased. The company generates revenue by offering online casinos, online sports betting, and social gaming directly to the end customer through its websites or apps. The company generates revenue through business-to-consumer (B2C) and business-to-business (B2B) models.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.